MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
*Portfolio Companies: Canaan
Amicus Therapeutics, Inc (NASDAQ: FOLD)*
Organization & Developments: Amicus
Parents
Amicus Therapeutics, Inc (NASDAQ: FOLD)*
Children
*Amicus develops pharmacological chaperones - oral therapies that bind to and stabilize the affected proteins, restoring their shape, proper trafficking, and biological activity.
*Biolink
*Drugs for genetic enzyme deficiencies
*This novel, next-generation approach offers the potential to improve treatment options for patients with genetic diseases.
2014: Standing on a Ledge Once Again, Amicus Holds Breath for Latest Study
2015: Amicus Up As FDA, EU Green-light Quick Drug Filings FOLD
2016: Amicus Therapeutics: Undervalued With Catalysts On The Way - Amicus Therapeutics, Inc. (NASDAQ:FOLD)
2017: Amicus Therapeutics: Small Biotech Seems To Have The 'Big Mo' - Amicus Therapeutics, Inc. (NASDAQ:FOLD)
2017: Amicus Therapeutics: Upside Via Regulatory Updates And Pompe Program - Amicus Therapeutics, Inc. (NASDAQ:FOLD)
2018: Amicus Finally Wins FDA Nod, Will Price Fabry Drug Below Rivals
2018: Amicus Therapeutics -10% on missed CMA in Europe_seekingalpha.com
2018: Amicus Therapeutics: Pompe Data Strengthens Bullish Thesis -seekingalpha.com
2018: Amicus Therapeutics: Regulatory Update And Financing Add To Bull Case_seekingalpha.com
2018: Amicus Therapeutics: Several Exciting Catalysts In 2018 - Amicus Therapeutics, Inc. (NASDAQ:FOLD)
2018: Amicus Therapeutics: What To Expect In 2018 - Amicus Therapeutics, Inc. (NASDAQ:FOLD)
2019: 65--Amicus Therapeutics, 65IB, 36F79719D0108 Effective 03-15-2019
2019: Amicus initiated with a Buy at H.C. Wainwright FOLD
2019: Amicus Looks To Push Gene Therapy Pipeline After Latest Expanded Agreement_seekingalpha.com
2019: Amicus Offers First Look At Gene Therapy Work With Batten’s Data
2019: Amicus Therapeutics: Looking A Few Years Ahead_seekingalpha.com
2019: Amicus: One Down, One To Go, More In The Lab - Amicus Therapeutics, Inc. (NASDAQ:FOLD)
2019: What Makes Amicus Therapeutics An Exciting Buy Now_seekingalpha.com
2020: Amicus Therapeutics: Inflection Point Coming In 2021
2021: Amicus Therapeutics Carves Out Gene Therapy Portfolio, Reduces Upside Optionality
2022: Amicus: Another Day, Another Delay, Pretty Much The Same Silly Reason_seekingalpha.com
2023: Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
2023: Amicus Therapeutics: Finally The FDA Inspection Is Done (NASDAQ:FOLD)
2023: Amicus Therapeutics: Limited Label For Pombiliti And Opfolda And Why It May Not Matter
2023: Amicus Therapeutics: The Right Play Now
2023: Launch of new Pompe treatment ‘exciting,’ Amicus chairman says
2024: 'Boring' Amicus Therapeutics Is Making Progress
2024: Amicus Therapeutics Announces Second Quarter 2024 Financial
2024: Amicus Therapeutics, Inc. (NASDAQ:FOLD) Is Expected To Breakeven In The Near Future
2024: Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
2024: Amicus Therapeutics: Cheap Heading Into 2025_ seekingalpha.com
2024: Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
2024: Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Jumps
*Key People: Amicus
Finance & Acquisitions: Amicus